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ABSTRACT
Progress toward establishing the effectiveness of biopsychosocial treatment for patients with sexual 
problems is limited by the lack of brief measurement tools assessing change across various domains of 
the treatment model. We developed and psychometrically validated a new clinical evaluation tool, the 
Sexual Function Evaluation Questionnaire (SFEQ) to meet this gap. The SFEQ combines into a single scale 
the best performing items from two instruments that were piloted in a UK sexual problems clinic (n = 486): 
the Natsal-SF Clinical Version and the National Sexual Outcomes Group 1 measure. Internal construct 
validity evidence from exploratory and confirmatory factor analyses supported a 16-item measure con-
sisting of one overarching dimension of overall sexual function distributed along four subscales: problem 
distress, partner relationship, sex life, and sexual confidence. The measure had satisfactory configural, 
metric, and scalar invariance over time and across groups based on gender, ethnicity, and age. 
Correlations with patient depression and anxiety demonstrated external validity. Change in scores over 
the course of therapy varied as predicted, with greater improvement in younger patients and in areas 
more amenable to change via therapy (sexual confidence and problem distress). The SFEQ is a brief clinical 
tool with the potential to assess sexual function and evaluate the effectiveness of biopsychosocial 
treatment programs.
Treatment of sexual difficulties often requires addressing com-
plex causes rooted in psychological, relational, and socio- 
cultural spheres (McCabe et al., 2010). The biopsychosocial 
model takes account of these wide-ranging influences on sexual 
dysfunction (Brotto et al., 2016) and is thus recommended as 
a framework for understanding and treating sexual problems 
(McCabe et al., 2010; Thomas & Thurston, 2016). In recogniz-
ing the multiple levels of influence on the experience of disease, 
the biopsychosocial model represents a philosophy of clinical 
care that recognizes the importance of patient subjective 
experience in accurate diagnosis and effective treatment 
(Borrell-Carrió et al. 2004). Biopsychosocial treatment 
approaches typically combine psychological approaches (such 
as mindfulness training or cognitive-behavioral therapy) with 
pharmacological treatment (for example, McCabe & Althof, 
2014; Schmidt et al., 2014), and they rely on open patient– 
clinician relationships and intuitive diagnostic skills (Borrell- 
Carrió et al., 2004).
Despite their promise, clear biopsychosocial treatment 
models and algorithms are still in development, and there are 
practical challenges in ensuring interdisciplinary training and 
collaboration across clinical providers (Berry & Berry, 2013; 
Brotto et al., 2017; Pyke & Clayton, 2015). One issue with 
biopsychosocial treatment is the lack of agreement about 
what constitutes a successful outcome, given the primacy 
given to patient assessment of the problem (Leiblum, 2006; 
Philips, 2009). Another issue is that variation in approaches 
across practitioners, and the importance of dynamics between 
clinician and patient, makes it difficult to identify and replicate 
the “effective ingredients” of the approach.
A third issue is the limited number of valid and appropriate 
instruments that could be employed to demonstrate effective-
ness (Pyke & Clayton, 2015; Tabatabaie, 2014). Widely used 
“gold standard” instruments such as the International Index of 
Erectile Function (IIEF; for men; R. C. Rosen et al., 1997) and 
the Female Sexual Function Index (FSFI for women; R. Rosen 
et al., 2000), are too narrowly focused. For instance, both 
assume vaginal penetration and have limited questions on the 
relationship or on patient assessment of “bother.” Another 
measure widely used in clinical settings – The Changes in 
Sexual Functioning Questionnaire - Short Form (CSFQ-14) 
(Keller et al., 2006) – is brief and less focused on physiological 
response but does not assess the sexual relationship and does 
not include items on sexual confidence that is often a target of 
sex therapy (Leiblum, 2006).
Indeed, while many measures of sexual (dys)function exist, 
few are designed to offer a holistic assessment in clinical set-
tings. Limitations of existing measures include weak psycho-
metric properties, length (too long for clinical use), and 
applicability to only specific groups, such as women only, 
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men only, those in longer term relationships, or with opposite- 
sex partners (Arrington et al., 2004; Daker-White, 2002). 
A review of potential sex therapy outcome measures focused 
on those that were potentially sensitive to change; applicable 
across a wide range of male and female sexual and relational 
problems; had strong psychometric properties; and were easy 
to administer and complete (Tabatabaie, 2014). Although sev-
eral measures were identified in the review as meeting these 
criteria, none spanned across all dimensions of sexual pro-
blems, sexual relationships, and general quality of sex life 
(Tabatabaie, 2014). There is thus a key gap in the field for 
a brief clinical evaluation tool that can assess change in sexual 
function holistically, that is: sexual difficulties; relational 
aspects of sexual function; and patient feelings about problems 
(e.g., satisfaction, distress, and confidence).
In order to assess the possibilities for a new clinical evalua-
tion tool capturing change in different domains of the biopsy-
chosocial model, we carried out a psychometric evaluation of 
two instruments that were piloted in a sexual problems clinic in 
the UK: the Natsal-SF Clinical Version (NSFC) and NSOG1. 
The Natsal-SF-Clinical Version was adapted from the Natsal- 
SF measure, a brief (17-item) bespoke measure for the third 
British National Survey of Sexual Attitudes and Lifestyles 
(Natsal 3). The Natsal-SF was designed for community health 
surveys to provide an annual population prevalence estimate of 
sexual function (Mitchell et al., 2012). It measures a general 
construct of sexual function, with three specific factors mea-
suring sexual problems, sexual relationship, and appraisal of 
sex life. The Natsal-SF has good discriminant validity (odds 
ratio [OR] 2.667 for clinical group), acceptable test–retest 
reliability (r = 0.72), and good model fit (Comparative Fit 
Index 0.963; Tucker Lewis Index 0.951; and Root Mean 
Square Error of Approximation 0.064; Mitchell et al., 2012). 
However, the Natsal-SF is unsuitable for clinical use because of 
its 1-year reporting period and lack of detailed information on 
the severity and distress of sexual problems. In 2014, the first 
author was requested to adapt the Natsal-SF for clinical use. In 
addition to small tweaks to instructions and wording, the three 
significant adaptations were as follows: to reduce the timeframe 
for reporting from past year to past month; to include items on 
distress about problems; and to remove the final item on help- 
seeking (Mitchell et al., 2016). The Natsal-SF clinical (NSFQ) 
was then piloted in a single sexual problems service in London 
led by KG. In parallel, a group of cross-specialty clinicians 
formed the UK National Sexual Outcomes Group (NSOG), 
with a remit to design a brief evaluation measure for use in 
their services. Committed to biopsychosocial treatment of sex-
ual problems, the group was motivated to address a perceived 
gap in suitable measures (i.e. brief and holistic). The first 
version they developed (NSOG1) – a brief 8-item measure – 
was designed via discussion between group members and 
focused on self-appraisal in terms of confidence, satisfaction, 
distress, quality of sex life and importance of sex. The measure 
was not psychometrically validated but was nonetheless piloted 
by the group across several UK sexual problems services, 
including alongside the Natsal-SF in the service led by KG. 
We originally set out to validate each measure separately. It 
soon became clear that due to limitations inherent in each 
measure and non-overlap in topic coverage, a single combined 
measure would be stronger and have wider applicability. This 
study investigated the internal and external validity of the 
combined instrument (the SFEQ; male and female versions) 
and its responsiveness to change over a course of therapy 
sessions in a sexual problem clinic setting.
Method
Sample
The study used fully anonymized records from 486 patients 
at the Sexual Problems Assessment and Treatment Service, 
Central and North West London NHS Foundation Trust 
collected between August 2015 and December 2018. The 
model of this service included assessment (and possible 
treatment) by both a doctor trained in psychosexual medi-
cine and psychosexual therapy by a clinical psychologist. 
Patients supplied information on the NATSAL-SF Clinical 
and/or NSOG prior to their initial patient assessment, and 
on repeated occasions during their involvement with the 
service. The full sample comprised 486 patients (45.9% 
female) who supplied data at Time 1 (initial assessment; 
see Table 3). This was a sample for the analysis of internal 
validity (EFA and CFA) and external validity. Measurement 
invariance across gender, age, and ethnicity was measured in 
271 patients supplying information at time 1 and time 2. Of 
the full sample, 106 patients supplied information at all 5 
possible time points and comprised the sample for analysis 
of change in overall scores and subscales over the course of 
treatment. At each analytic stage, the largest possible sample 
was used, based on the availability of relevant patient record 
information.
Measures
Details of Natsal-SF Clinical (from this point on, NSFC) and 
NSOG items with response distributions are provided in 
Tables 1–2. For NSFC items on sexual problems, the original 
questionnaire contained measures of both frequency and dis-
tress. As exploratory analyses indicated that distress items 
provided a better model fit than frequency items, we selected 
these (with the exception of the item on anxiety, where the 
frequency measure was selected to aid interpretability). NSOG 
items are shown using the original 11-point response scale. To 
align NSOG items with the 4- and 5-point NSFC scales, the 
main analysis used NSOG items rescaled as follows: 0/1 = 1, 2/ 
3 = 2, 4/6 = 3, 7/8 = 4, 9/10 = 5. Supplementary analyses 
indicated no loss of information using this approach.
Patient records also contained information on gender, age, 
ethnicity, sexual orientation, clinician diagnosis, depression 
using the PHQ-9 (Arroll et al., 2010), anxiety using the 
GAD7 (Spitzer et al., 2006), alcohol use disorder using the 
AUDIT (Babor et al., 2001) and non-prescription drug use; 
all measured at the initial assessment only. Data from the initial 
patient assessment were used for the main analysis of internal 
consistency and external validity, restricting the sample to 
patients completing both the Natsal-SF Clinical and NSOG 
measures.
2 K. MITCHELL ET AL.
Analysis
Internal Validity and Measurement Invariance
Based on the full sample (n = 486), exploratory factor analysis 
(EFA) using Maximum Likelihood (ML) with varimax rotation 
was used to determine the number of underlying factors repre-
sented by the combined set of 23 items (NSFC and NSOG). 
Indicator items with low loadings (<.3) on all factors were 
removed, as were items with cross-loadings. We also removed 
items loading on a factor that contained fewer than three such 
items (even if loadings were >0.3). This is because a minimum of 
three items is needed to identify a latent construct corresponding 
to a subscale (Koran, 2020). Confirmatory factor analysis (CFA) 
confirmed that a four-factor solution had the best fit. The four 
factors were as follows: problem distress; partner relationship; 
overall sex life; sexual confidence. Table 5 shows the final struc-
ture and factor loadings (item loadings on each factor are shown 
in Supplementary Table S1). In subsequent confirmatory factor 
analysis (CFA; Table 5), indicator cutoffs applied to assess abso-
lute model fit were >.95 for the Confirmatory Fit Index (CFI) 
and Tucker-Lewis Index (TLI), <.06 for the root mean square 
error of approximation (RMSEA) and <.08 for the standardized 
root mean residual (SRMR; Hu & Bentler, 1999). The CFA 
confirming good model fit allowed extension to a second-order 
CFA to confirm the presence of a higher-order factor and 
permitted testing of measurement invariance as detailed below.
Measurement invariance with respect to gender, age 
(under 30 years vs. 30 years or more) and ethnicity (white 
vs. ethnic minority) and time was assessed. Across time, the 
interval between the first and third measurement points was 
selected as the maximum interval with a sufficiently large 
sample size (n = 193). Across longer intervals (e.g., com-
paring time 1 with time 4 or 5), sample sizes for repeated 
measures did not permit model convergence. Configural 
invariance (similar factor structure), metric invariance 
(similar factor loadings), and scalar invariance (similar 
intercepts and factor loadings) across gender, age, and 
ethnicity were assessed using multigroup models. For con-
figural invariance, we assessed the absolute fit of 
a multigroup model with no equality constraints. For 
metric and scalar invariance, we compared the fit of nested 
constrained and unconstrained models (Putnick & 
Bornstein, 2016). Configural, metric, and scalar invariance 
across time was assessed using longitudinal models 
(Widaman et al., 2010). Following recommended practice, 
we used multiple indicators to assess invariance, including 
differences in model chi-square, CFI, RMSEA, and SRMR 
(Putnick & Bornstein, 2016). Target cutoffs for changes in 
model fit statistics between constrained and unconstrained 
models were set at −0.01 for CFI, 0.01 for RMSEA and 
0.015 for SRMR, although there is currently little consensus 
on these (Putnick & Bornstein, 2016).
Table 1. Distribution of responses, Natsal-SF clinical version (n = 486).
Sexual problems Frequency (%)
Never Not very often Sometimes Very often
Always/did not 
have sex last 
month due to 
this
1) Felt anxious during sex* 11.2 12.8 24.4 26.0 25.6
Distress
Not a problem Not at all distressed A little distressed Fairly distressed very distressed
2) Lacked interest in having sex 24.0 12.0 21.9 26.7 15.4
3) Lacked enjoyment in having sex 23.5 9.1 22.6 26.5 18.4
4) Felt physical pain as a result of sex 41.8 11.0 12.4 15.0 19.8
5) Felt no excitement or arousal 
during sex
28.5 11.2 20.2 23.8 16.4
6) Did not reach a climax 28.1 14.3 21.7 19.8 16.2
7) Reached a climax more quickly 
than would like
51.2 14.9 13.6 8.9 11.4
8) Erectile problems (men)/dry 
vagina(women)
21.5 9.3 15.8 23.9 29.6
Sexual relationship with partner Agree strongly Agree Neither agree nor disagree Disagree Disagree strongly
9) My partner and I share about the 
same level of interest in having sex
11.8 20.0 14.5 34.9 18.8
10) My partner and I share the same 
sexual likes and dislikes
13.7 39.5 27.7 16.0 3.1
11) My partner has experienced 
sexual difficulties in the last month
10.6 16.9 11.0 28.7 32.7
Always Most of the time Sometimes Not very often Hardly ever
12) Feel emotionally close to partner 
when engage in sex together
35.7 39.1 16.8 5.5 2.9
Perceptions of sex life Agree strongly Agree Neither agree nor disagree Disagree Disagree strongly
13) I feel satisfied with my sex life 2.6 6.0 15.9 42.8 32.8
14) I feel distressed or worried about 
my sex life
32.8 47.5 10.6 5.3 3.8
15) I have avoided sex because of 
sexual difficulties (my own or 
partner’s)
27.2 35.3 13.9 14.8 8.8
These distributions exclude missing information. There was missing information for 11–14% of NSFC problem distress items, 47–51% of NSFC partner relationship items 
(these were only applicable to patients having a regular sexual partner for the past month), 3–4% of NSFC sex life items and 1% of NSOG items. 
*Because anxiety and distress overlap conceptually, frequency rather than distress was used to score severity on this item.
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Analyses all used Mplus Version 8.1 (Muthén & Muthén, 
Muthén and Muthén, 1998/2017), with missing information 
handled using the Full Information Maximum Likelihood 
method.
External Validity
Two procedures were used. First, to assess the validity of 
individual patient reported problems, we examined bivariate 
associations between NSFC items on individual problems and 
clinician diagnoses recorded at the initial assessment where 
this information was available (n = 415). Although the SFEQ 
measure overall assesses more than sexual problems, this infor-
mation can help establish the potential clinical utility of the 
measure.
Second, to assess the validity of the final measure, we exam-
ined its associations with patient depression (PHQ-9 cutoff 
score of 10), anxiety (moderate and severe, cut-off scores, 
respectively, 10 and 15 on GAD7), alcohol use in excess of 
recommended guidelines (AUDIT C-score 4+ for men, 3+ for 
women) and non-prescription drug use using logistic regres-
sion. Anxiety is strongly implicated in sexual dysfunction 
(Barlow, 1986) and there is strong evidence that depression/ 
anxiety and sexual dysfunction can be comorbid (Laurent & 
Simons, 2009). Alcohol and recreational drug use are obviously 
implicated in Substance/Medication-Induced Sexual 
Dysfunction, and alcohol can be a factor in erectile difficulties 
and low desire (American Psychiatric Association, 2013). Few 
community studies report on alcohol and recreational drug use 
as risk factors, although one key study found evidence of 
association between specific difficulties and alcohol or recrea-
tional drug use in community populations (Johnson et al., 
2004). Based on existing evidence, we would expect 
a reasonably high correlation between depression and anxiety 
and a less strong correlation between alcohol and recreational 
drug use. Note that, as a study taking place in a real-world 
clinic, choice of external variables was restricted to data routi-
nely collected from patients.
Responsiveness to Change
Change in factor scores for the combined measure, and for 
subscales over a course of five therapy sessions, was explored 
among patients for whom data were available at all five time 
points (n = 106). This was the maximum number of sessions 
for which sufficient patient data were collected to permit sub-
group analyses. We calculated effect sizes by dividing the 
change in score over time by the standard deviation of the 
change score. As a study based on existing clinical data, we did 
not have a control group (patients who did not receive ther-
apy). Observing change per se may not be helpful since even if 
the change is in the expected direction it may be unclear what is 
being picked up (De Vet et al., 2011). To assess whether the 
change was meaningful, we thus undertook two different sen-
sitivity analyses. These sought to test whether differences in the 
magnitude of change were as expected across subgroups of 
patients and domains of sexual function. We expected to 
observe the following differences:
(1) Change with therapy may be more pronounced among 
younger patients since they are less likely to have physical 
health comorbidities (Field et al., 2013). It is also plausible 
that young people are less likely to have attitudes toward 
sex and experiences of sexual problems that have become 
entrenched over a significant period of time.
Table 2. Distribution of responses NSOG items (n = 486).
11-point response scale (%)
0 1 2 3 4 5 6 7 8 9 10
Not important Important
1) How important is your sex life to you? 1.0 0.2 1.4 1.7 2.1 3.3 3.5 17.1 22.7 14.4 32.6
Not severe Severe
2) How severe is your sexual problem? 0.8 0.6 2.7 3.3 2.7 10.2 8.7 21.4 19.1 12.5 17.9
Poor Good
3) What is the quality of your sexual life? 16.2 7.1 11.9 17.5 9.2 10.6 12.3 6.2 5.0 2.1 2.1
Not confident Confident
4) How sexually confident are you? 11.6 5.6 9.5 13.9 10.2 13.7 11.8 9.8 6.6 3.5 3.7
Not well Well
5) How well does your body work sexually? 11.3 6.7 13.5 15.6 10.6 11.7 8.5 9.4 6.7 2.9 3.1
Not satisfied Satisfied
6) How satisfied are you with your sex life? 22.2 10.6 16.6 13.5 9.1 10.4 8.5 4.4 2.1 1.5 1.2
Not distressed Distressed
7) How distressed are you by your sexual problem? 0.8 1.7 5.2 4.6 4.3 5.6 8.7 15.3 19.2 15.1 19.6
Not confident Confident
8) How confident do you feel engaging in sexual activity? 11.2 6.9 13.1 10.8 10.8 12.1 11.0 10.2 4.8 4.8 4.4
For the main analyses, NSOG item responses were combined as follows: 0/1 = 1, 2/3 = 2, 4/6 = 3, 7/8 = 4, 9/10 = 5. These distributions exclude missing information. 
There was missing information for 1% of NSOG items.
Table 3. Sample information (n = 486).
n %
Gender Female 223 45.9
Male 263 54.1












Sexual orientation Bisexual 10 2.1
Heterosexual 265 54.5
Missing 211 43.4
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(2) Therapeutic intervention should produce more change 
in issues closely related to individual confidence and 
distressing feelings about specific problems. This is 
partly because the biopsychosocial model gives primacy 
to patient subjective perceptions of their experiences 
and typically seeks to support them in understanding 
the problem and changing how they respond to their 
experiences (Brotto & Basson, 2014). In contrast, 
broader subjective assessments of overall sex life (e.g., 
satisfaction) are influenced by a wide range of factors 
(including the presence or absence of a partner), and 
relational function is partly dependent on the behavior 
of another (Hewison et al., 2017). Each of these might 
be less amenable to change.
All analyses used Stata version 16.0.
Results
Information on NSFC and NSOG items was collected from 486 
patients at the first appointment. Table 3 shows sample char-
acteristics. The full sample (n = 486) comprised 45.9% female; 
62.1% white; and 41.6% were under 30, 46.7% were 30–49, and 
11.7% were 50 or over. Clinic data on sexual orientation were 
incomplete (43.4% missing). Table 4 shows primary clinician 
diagnoses according to patient gender. For men, the most 
common primary clinician diagnoses were erectile problems 
(erectile “difficulties”/“disorder”/“dysfunction,” n = 137, 52%), 
early ejaculation (n = 47, 18%), and hyposexual desire disorder 
(n = 21, 8%). For women, the most common primary clinician 
diagnoses were genito-pelvic pain/penetration disorder 
(n = 131, 59%), anorgasmia (n= 25, 11%) and sexual interest/ 
arousal disorder (SIAD) (n= 14, 6%). The Natsal-SF Clinical 
asks about eight sexual problems. Among those reporting any 
problem “sometimes,” “often” or “very often,” there was 
a median of four problems per patient (data not shown).
Structural Validity and Measurement Invariance
Staged EFA suggested a four-factor structure. Ten items per-
formed poorly due to low loadings, insufficient number of 
items per factor or cross-loadings. These were NSFC items on 
anxiety, pain, premature orgasm, erectile problems (men)/ 
vaginal dryness (women), partner’s sexual difficulties; and 
NSOG items on importance of sex life, severity of sexual 
problem, distress over sexual problem, quality of sex life and 
satisfaction with sex life. The five items from the NSOG and the 
NSFC items on anxiety and partner’s sexual difficulties were all 
discarded. The remaining items – pain, premature orgasm, 
erectile problems (men)/vaginal dryness (women) – were indi-
vidually not well aligned with one another within this clinic 
population. However, the extent of distress from whichever of 
these specific problems was most burdensome was sufficiently 
well aligned with the other less specific problems (lack of 
enjoyment, no interest in sex, no excitement) to warrant inclu-
sion in the final subscale called “problem distress.” Thus, the 
NSFC items on pain, premature orgasm, erectile problems 
(men)/vaginal dryness (women) were retained for patient com-
pletion, and a new item (most distress caused by any of these 
three problems) was created to contribute to the overall score. 
This allowed us to retain information on specific problems.
A four-factor structure was supported by the CFA, with 
factors representing problem distress, partner relationship, 
sex life, and sexual confidence. A second-order CFA model 
confirmed that all four factors loaded on to a single underlying 
factor. Model fit was satisfactory (CFI = 0.940, TLI = 0.924, 
SRMR = 0.054, RMSEA = 0.059 with p ≤ .05 equal to 0.085). 
Table 5 shows the factor structure and loadings for the com-
bined NSFC/NSOG instrument.
Configural invariance of the four-factor structure was satis-
factory: across gender, age, ethnic group, and time, CFI was 
0.92–0.93, RMSEA 0.05–0.07, and SRMR was <0.08 for all 
models. Metric invariance was confirmed across gender, age 
group, ethnic group, and time for all indices of model fit. Scalar 
invariance received partial confirmation: although differences 
in model chi-square were statistically significant for all groups, 
Table 4. Primary clinician diagnosis by patient gender*.
n %
Men Erectile difficulties/disorder/dysfunction 137 52
Hyposexual desire disorder 21 8
Early ejaculation 47 18
Delayed ejaculation 20 8
Partner has sexual difficulties 8 3
No diagnosis 30 11
Women Genito-pelvic pain/penetration disorder 131 59
Anorgasmia 25 11
Sexual interest/arousal disorder 14 6
Partner has sexual difficulties 11 5
Anaerobic bacterial vaginosis 1 0
No diagnosis 41 18
*The distribution of diagnoses in part reflects that the clinic was primarily able to 
offer treatment for Erectile Difficulties (men) and Genito-Pelvic Pain/Penetration 
Disorder (women).
Table 5. Factor structure and loadings for a combined NSFC/NSOG instrument 




Factor 1: Problem 
distress 
(NATSAL Q2,3,5 plus 
6, 7, 4, 8; Table 1)
Distress due to no interest in sex 0.75
Distress due to no enjoyment of sex 0.78
Distress due to no excitement/arousal 0.75
Distress from no climax; climax quicker 
than would like; pain; or erectile 
difficulties/vaginal dryness (whichever 
causes the most distress)
0.50




share same level of interest in sex 0.76
share same sexual likes and dislikes 0.63
feel emotionally close to partner during 
sex
0.40




Satisfied with sex life 0.66
Distressed by sex life −0.62
Avoided sex −0.73





How well body works well sexually 0.64







Higher scores for factors 1, 2, and 3, and lower scores for factor 4, denote lower 
sexual function. In the overall measure, higher scores denote lower function.*
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one or more differences in CFI, RMSEA, and SRMR fell within 
the cutoffs applied. (For further details of tests for measure-
ment invariance, see Supplemental File Table S1.)
External Validity
To establish the validity of patient reports of specific problem 
distress, we explored associations between relevant SFEQ items 
and common clinician diagnoses. Patient reports of distress 
were generally in agreement with clinician diagnoses. For 
example, 88% of men diagnosed with erectile problems 
reported being fairly or very distressed by erectile problems, 
compared to only 23% of men diagnosed with hyposexual 
desire disorder. Similarly, 92% of women diagnosed with anor-
gasmia reported being fairly or very distressed by inability to 
climax, compared to 36% of women diagnosed with genito- 
pelvic pain/penetration disorder. (Further details provided in 
the Supplemental File, Table S2.)
To establish the validity of the overall score, we used infor-
mation supplied by patients on mental health and health beha-
viors. Of the full sample of 486 at first clinic appointment, 222 
patients supplied information on depression, 217 on anxiety, 
222 on alcohol use, and 234 on non-prescription drug use. 
Controlling for patient gender and age, combined NSFC/ 
NSOG factor scores were associated with a greater likelihood 
of moderate and severe anxiety and of depression (Table 6). 
These associations were all in the expected direction, confirm-
ing external validity. As expected, the combined measure was 
not associated with alcohol or non-prescription drug use (not 
shown).
Responsiveness to Change
There were 106 patients (male n = 52; female n = 54) who 
completed the NSFC and NSOG instruments across a sequence 
of five therapy sessions. As shown in Table 7, the combined 
measure detected an improvement in scores across both 
younger (18–29 year old) and older (30–74 year old) age 
groups (mean change −0.35 (SD 0.47) for 18–29 year olds 
and mean change −0.17 (0.40) for patients aged 30–74).
As expected, effect sizes were larger among younger patients 
(effect size 0.7 for 18–29 year olds; and 0.4 for 30–74 year olds). 
Effect sizes were also larger for the problem distress and con-
fidence subscales than for the partner relationship and sex life 
subscales: among 18–29 year olds effect size for problem dis-
tress was 0.7 and sexual confidence was 0.9 compared with 0.4 
for partner relationship and 0.4 for sex life (Table 7 and 
Figure 1). Thus, our second expected difference was confirmed 
in the data. Confirmation of both these expected differences 
across patient groups and subscales suggests that the change 
detected by the SFEQ is meaningful.
Discussion
The SFEQ is a brief (16-item) clinical measure that captures the 
effects of biopsychosocial intervention on sexual problem dis-
tress, overall quality of sex life, partner relationships and sexual 
confidence. The SFEQ was designed by combining the best- 
performing items from two recently developed clinical mea-
sures: the Natsal-SF Clinical (15 items) and the NSOG1 (3 
items). It has a good model fit (internal validity) and is asso-
ciated with anxiety and depression (external validity). 
Measurement invariance (configural and metric) was estab-
lished across gender, age, ethnicity, and time. We found some 
evidence for scalar invariance, although there is no established 
consensus regarding appropriate cutoffs for differences in 
model fit (Putnick & Bornstein, 2016). By combining measure-
ment of specific problems with “softer” therapy goals, such as 
confidence, satisfaction, and improved sexual relationship, we 
believe the SFEQ is uniquely placed as an evaluation tool for 
holistic approaches to addressing sexual problems.
In addition to brevity and simplicity, the SFEQ is straight-
forward for patients to understand and complete; suitable for 
all genders, all sexual orientations and for different age and 
ethnic groups. Four of the items on specific problem distress 
are combined, to give a 13-item measure for scoring purposes. 
A note on scoring is provided in the Supplementary File.
A possible limitation of the SFEQ is the lack of detailed 
information on specific sexual problems, although for clinic 
patients this is likely to be compensated for by clinician notes. 
Table 6. Associations between combined measure and patient anxiety, depression, and substance use.
Outcome 
(sample prevalence %)
Moderate anxiety (n = 217) (31%) Severe anxiety (n = 217) (13%) Depression (n = 222) (26%)
OR (95% CI) p OR (95% CI) p OR (95% CI) p







Sample size 217 217 222
Moderate anxiety: GAD7 score 10+, Severe anxiety GAD7 score 15+, depression PHQ9 score 10+. Models were all adjusted for gender and age. OR = odds ratio, 
CI = confidence interval, p = probability
Table 7. Mean change in the overall and subscale scores over five therapy 
sessions, among patients in different age groups.
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−0.35 (0.47) <.001 0.7 −0.17 
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It is important to note that the SFEQ is an evaluation tool, not 
a diagnostic one. Although a strength of the SFEQ is the 
inclusion of questions about the sexual relationship context, 
this adds complication to scoring, since these items are not 
applicable to patients with no regular sexual partner in the last 
month. In this study, our statistical software imputed missing 
data, but this technique may not always be available. Further 
work is required to establish an easy-to-use scoring system that 
does not rely on imputation.
The SFEQ has a number of strengths and limitations with 
regard to gender and sexual identity. The male and female 
versions of the SFEQ are identical except for an item on 
vaginal dryness (female version) and erectile difficulties 
(male version). The benefits of this include ease of compar-
ison in effectiveness trials, and simplicity in monitoring and 
audit of clinic work. It also raises the possibility of utility in 
couple therapy in which sexual function is a key focus, along-
side measures such as the 28-item Golombok Rust Inventory 
of Marital State (Rust & Golombok, 2010) and generic 
Clinical Outcomes Routine Evaluation – Outcome Measure 
therapy outcome measure (Evans et al., 2002). In theory, the 
measure should be relevant to anyone with a vagina or 
a penis, regardless of their gender identity, but testing for 
validity in trans populations was not possible in this study 
and should be a focus for future work, particularly given the 
paucity of measures relevant to this group. Similarly, due to 
missing data, we are limited in exploring the suitability of the 
measure across patients according to sexual identity and 
gender(s) of sexual partners, although the measure can be 
completed irrespective of these. Given the known variation in 
reporting of distressing sexual problems by sexual orientation 
and partner gender (Waterhouse & Burkill, 2019), this should 
be another focus for future research. As a trade-off for 
brevity, there are aspects of sexual functioning that may be 
addressed in the course of psychosexual therapy but are not 
assessed in the SFEQ. This includes things like sexual com-
munication skills, acceptance of sexuality and satisfaction 
with treatment.
A limitation of the study is that we were unable to assess 
test–retest reliability, although this has already been established 
for items included in the Natsal-SF in a community sample 
(Mitchell et al., 2012). This study used already-collected clinical 
monitoring data and the retrospective design meant that it was 
not possible to correlate the SFEQ against widely used, more 
specialized measures of sexual function (Tabatabaie, 2014). 
Clinician diagnoses did not indicate the severity of the pro-
blem, so we were unable to use these as a measure of validity for 
the whole measure. Nonetheless, we did find that diagnoses 
correlated reasonably with patient-reported problems, espe-
cially given that exact correspondence is not to be expected 
(King et al., 2007). The measure was validated in a multi- 
disciplinary service including medical and psychosexual inter-
ventions. Due to the nature of the combined assessment model 
(psychological and pharmacological), it is not possible to estab-
lish which aspects of the assessment or intervention the effects 
noted were linked to, and therefore which were responsible for 
the largest effects. Future evaluation work employing the SFEQ 
may be able to tease out these effects. A further limitation is 
that the clinic was primarily able to offer interventions for 
erectile difficulties and genital pelvic pain penetration disorder. 
This meant that other sexual problems – such as SIAD (sexual 
interest/arousal disorder) – are under-represented in the 
patient group on which the SFEQ has been validated.
Measures such as the SFEQ are critical to efforts to 
establish the effectiveness of biopsychosocial treatment mod-
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Factor 1 problem distress
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Factor 4 low confidence
Figure 1. Change in SFEQ subscales over five sessions, n = 106.
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support for service provision. Clinically significant sexual 
problems affect a sizable minority of people; in Britain, 
around 4% of men and women aged 16–74 report sexual 
problems meeting clinical severity criteria, only a third of 
whom have sought professional help (Mitchell et al., 2016). 
Studies suggest that far more people would like professional 
help than actually receive it (Dunn et al., 2017). Although 
this is partly due to individual beliefs about sex and the 
appropriateness of seeking medical help (Mitchell et al., 
2016; Moreira et al., 2005), it is also true that free or 
affordable therapeutic clinics are scarce in most countries. 
Sexual problems, despite their prevalence and impact on 
mental and relational well-being, receive scant attention 
from policymakers (Mitchell et al., 2013; Population Health 
Directorate, 2019), and public services are chronically under-
funded (Davis, 2019). Our hope is that measures such as the 
SFEQ can be used to demonstrate the effectiveness of the 
approach and therefore support clinicians to attract funding 
for services and to work collaboratively across disciplines 
(e.g., urology, clinical psychology, and gynecology).
In conclusion, we believe the SFEQ meets a critical gap in 
measurement tools to assess the effectiveness of biopsychoso-
cial treatment. As a free-to-use, noncommercial measure, we 
intend it to be accessible to publicly funded services providing 
holistic treatment for sexual problems.
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